References
- BurnsEMYusufNToll-like receptors and skin cancerFront Immunol2014513524744758
- AkiraSHemmiHRecognition of pathogen-associated molecular patterns by TLR familyImmunol Lett2003852859512527213
- SongPIParkYMAbrahamTHuman keratinocytes express functional CD14 and toll-like receptor 4J Invest Dermat20021192424432
- BauerSPigischSHangelDKaufmannAHammSRecognition of nucleic acid and nucleic acid analogs by Toll-like receptors 7, 8 and 9Immunobiology20082133–431532818406377
- SantoniMAndrikouKSotteVToll like receptors and pancreatic diseases: from a pathogenetic mechanism to a therapeutic targetCancer Treat Rev201541756957626036357
- OchiAGraffeoCSZambirinisCPToll-like receptor 7 regulates pancreatic carcinogenesis in mice and humansJ Clin Invest2012122114118412923023703
- AspordCTramcourtLLeloupCImiquimod inhibits melanoma development by promoting pDC cytotoxic functions and impeding tumor vascularizationJ Invest Dermatol2014134102551256124751730
- CraftNBruhnKWNguyenBDThe TLR7 agonist imiquimod enhances the anti-melanoma effects of a recombinant Listeria monocytogenes vaccineJ Immunol200517531983199016034143
- GoldingerSMDummerRBaumgaertnerPMihic-ProbstSMSchwarzSMHammann-HaenniSMNano-particle vaccination combined with TLR-7 and -9 ligands triggers memory and effector CD8(+) T-cell responses in melanoma patientsEur J Immunol201242113049306122806397
- ArandaFLlopizDDiaz-ValdesNAdjuvant combination and antigen targeting as a strategy to induce polyfunctional and high-avidity T-cell responses against poorly immunogenic tumorsCancer Res20117193214322421402711
- DrobitsBHolcmannMAmbergNImiquimod clears tumors in mice independent of adaptive immunity by converting pDCs into tumor-killing effector cellsJ Clin Invest2012122257558522251703
- EiroNOviesCFernandez-GarciaBExpression of TLR3, 4, 7 and 9 in cutaneous malignant melanoma: relationship with clinicopathological characteristics and prognosisArch Dermatol Res20133051596723179584
- GoldmanMCraftBSwatloskiTThe UCSC Cancer Genomics Browser: update 2013Nucleic Acids Res201341Database issueD949D95423109555
- BogunovicDO’NeillDWBelitskaya-LevyIImmune profile and mitotic index of metastatic melanoma lesions enhance clinical staging in predicting patient survivalProc Natl Acad Sci U S A200910648204292043419915147
- FridmanWHPagesFSautes-FridmanCGalonJThe immune contexture in human tumours: impact on clinical outcomeNat Rev Cancer201212429830622419253
- DajonMIribarrenKCremerIToll-like receptor stimulation in cancer: a pro- and anti-tumor double-edged swordImmunobiology201722218910027349597
- RidnourLAChengRYSwitzerCHMolecular pathways: toll-like receptors in the tumor microenvironment – poor prognosis or new therapeutic opportunityClin Cancer Res20131961340134623271799
- Gonzalez-ReyesSMarinLGonzalezLStudy of TLR3, TLR4 and TLR9 in breast carcinomas and their association with metastasisBMC Cancer20101066521129170
- SinghMKhongHDaiZEffective innate and adaptive anti-melanoma immunity through localized TLR7/8 activationJ Immunol201419394722473125252955
- ChaturvediAPierceSKHow location governs toll-like receptor signalingTraffic200910662162819302269
- SmitsELPonsaertsPBernemanZNVan TendelooVFThe use of TLR7 and TLR8 ligands for the enhancement of cancer immunotherapyOncologist200813885987518701762
- GauzziMCDel CornoMGessaniSDissecting TLR3 signalling in dendritic cellsImmunobiology20102159–1071372320561711
- SchreibeltGTelJSliepenKHToll-like receptor expression and function in human dendritic cell subsets: implications for dendritic cell-based anti-cancer immunotherapyCancer Immunol Immunother201059101573158220204387
- ArinaACorralesLBronteVEnhancing T cell therapy by overcoming the immunosuppressive tumor microenvironmentSemin Immunol2016281546326872631